A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.

To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of 5-fluorouracil (5-FU) in advanced or recurrent breast cancer patients who had been treated previously with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ando, M., Watanabe, T., Sasaki, Y., Ying, D. F., Omuro, Y., Katsumata, N., Narabayashi, M., Tokue, Y., Fujii, H., Igarashi, T., Wakita, H., Ohtsu, T., Itoh, K., Adachi, I., Taguchi, T.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1998
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2150334/
https://ncbi.nlm.nih.gov/pubmed/9667671
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados